MDxHealth SA (MDXH) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MDXH Stock Forecast

MDxHealth SA stock forecast is as follows: an average price target of $15.00 (represents a 563.72% upside from MDXH’s last price of $2.26) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

MDXH Price Target

The average price target for MDxHealth SA (MDXH) is $15.00 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 563.72% upside from MDXH's last price of $2.26.

MDXH Analyst Ratings

Buy

According to 12 Wall Street analysts, MDxHealth SA's rating consensus is 'Buy'. The analyst rating breakdown for MDXH stock is 0 'Strong Buy' (0.00%), 10 'Buy' (83.33%), 1 'Hold' (8.33%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

MDxHealth SA Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 26, 2022	Mark Massaro	BTIG	$15.00	$8.19	83.15%	563.72%

The latest MDxHealth SA stock forecast, released on Aug 26, 2022 by Mark Massaro from BTIG, set a price target of $15.00, which represents a 83.15% increase from the stock price at the time of the forecast ($8.19), and a 563.72% increase from MDXH last price ($2.26).

MDxHealth SA Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.26	$2.26	$2.26
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of MDxHealth SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MDxHealth SA's last price of $2.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 31, 2024	Lake Street		Buy	Initialise
Mar 07, 2024	BTIG	Buy	Buy	Hold
Mar 07, 2024	Piper Sandler	Overweight	Overweight	Hold
May 31, 2023	Noble Capital		Outperform	Initialise
May 31, 2023	UBS		Buy	Initialise
May 31, 2023	Goldman Sachs		Neutral	Initialise
May 31, 2023	Needham		Buy	Initialise
May 31, 2023	William Blair		Outperform	Initialise
May 31, 2023	RBC Capital		Outperform	Initialise
May 31, 2023	Cowen & Co.		Outperform	Initialise
May 31, 2023	Noble Capital Markets		Outperform	Initialise
May 16, 2023	BTIG	Buy	Buy	Hold
Aug 26, 2022	BTIG	Buy	Buy	Hold
Apr 26, 2022	Zacks Investment Research		Sell	Downgrade

MDxHealth SA's last stock rating was published by Lake Street on Oct 31, 2024. The company Initialise its MDXH rating from "null" to "Buy".

MDxHealth SA Financial Forecast

MDxHealth SA Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Dec 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.70M	$6.11M	$6.01M	$5.56M
Avg Forecast	$29.77M	$28.58M	$29.88M	$22.77M	$28.43M	$27.91M	$26.02M	$22.97M	$23.05M	$21.51M	$20.86M	$18.13M	$18.56M	$18.21M	$15.22M	$13.56M	$11.99M	$8.80M	$10.00M
High Forecast	$30.73M	$29.50M	$30.84M	$23.50M	$29.35M	$28.81M	$26.86M	$23.28M	$23.13M	$22.21M	$20.86M	$18.13M	$19.16M	$18.80M	$15.71M	$14.00M	$11.99M	$8.80M	$10.00M
Low Forecast	$28.35M	$27.22M	$28.45M	$21.68M	$27.08M	$26.57M	$24.78M	$22.66M	$22.97M	$20.49M	$20.86M	$18.13M	$17.67M	$17.34M	$14.49M	$12.91M	$11.99M	$8.80M	$10.00M
# Analysts	1	1	1	1	1	1	1	3	4	2	1	1	2	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.08%	0.51%	0.68%	0.56%

MDxHealth SA's average Quarter revenue forecast for Jun 23 based on 1 analysts is $15.22M, with a low forecast of $14.49M, and a high forecast of $15.71M. MDXH's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $14.70M (Mar 23).

MDxHealth SA EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Dec 21	Mar 21
# Analysts	1	1	1	1	1	1	1	3	4	2	1	1	2	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-7.08M	$-7.07M	$-6.74M	$-6.36M
Avg Forecast	$-26.29M	$-25.24M	$-26.39M	$-20.11M	$-25.11M	$-24.65M	$-22.98M	$-20.29M	$-20.35M	$-19.00M	$-18.42M	$-16.01M	$-16.39M	$-16.09M	$-13.44M	$-11.98M	$-10.02M	$-7.35M	$-8.35M
High Forecast	$-25.04M	$-24.04M	$-25.13M	$-19.15M	$-23.91M	$-23.47M	$-21.88M	$-20.01M	$-20.28M	$-18.09M	$-18.42M	$-16.01M	$-15.61M	$-15.32M	$-12.80M	$-11.40M	$-10.02M	$-7.35M	$-8.35M
Low Forecast	$-27.14M	$-26.06M	$-27.24M	$-20.76M	$-25.92M	$-25.44M	$-23.72M	$-20.57M	$-20.42M	$-19.61M	$-18.42M	$-16.01M	$-16.92M	$-16.60M	$-13.88M	$-12.36M	$-10.02M	$-7.35M	$-8.35M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.59%	0.71%	0.92%	0.76%

undefined analysts predict MDXH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than MDxHealth SA's previous annual EBITDA (undefined) of $NaN.

MDxHealth SA Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Dec 21	Mar 21
# Analysts	1	1	1	1	1	1	1	3	4	2	1	1	2	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.70M	$-8.69M	$-8.92M	$-7.72M
Avg Forecast	$-1.36M	$-2.30M	$-2.09M	$-6.48M	$-4.98M	$-5.65M	$-7.03M	$-8.08M	$-9.06M	$-12.76M	$-12.99M	$-14.15M	$-9.98M	$-14.19M	$-15.65M	$-19.54M	$-35.47M	$-40.93M	$-73.68M
High Forecast	$-1.27M	$-2.16M	$-1.96M	$-6.08M	$-4.67M	$-5.30M	$-6.60M	$-8.07M	$-7.25M	$-11.97M	$-12.19M	$-13.27M	$-7.13M	$-13.31M	$-14.68M	$-18.33M	$-35.47M	$-40.93M	$-73.68M
Low Forecast	$-1.41M	$-2.40M	$-2.17M	$-6.75M	$-5.18M	$-5.88M	$-7.33M	$-8.10M	$-11.78M	$-13.30M	$-13.54M	$-14.74M	$-12.12M	$-14.78M	$-16.31M	$-20.36M	$-35.47M	$-40.93M	$-73.68M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	0.24%	0.22%	0.10%

MDxHealth SA's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MDXH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

MDxHealth SA SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Dec 21	Mar 21
# Analysts	1	1	1	1	1	1	1	3	4	2	1	1	2	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.60M	$8.91M	$-15.47M	$2.56M
Avg Forecast	$22.38M	$21.49M	$22.47M	$17.12M	$21.38M	$20.98M	$19.56M	$17.27M	$17.33M	$16.18M	$15.68M	$13.63M	$13.95M	$13.69M	$11.44M	$10.19M	$9.02M	$6.62M	$7.52M
High Forecast	$23.11M	$22.18M	$23.19M	$17.67M	$22.07M	$21.66M	$20.19M	$17.51M	$17.39M	$16.70M	$15.68M	$13.63M	$14.40M	$14.14M	$11.81M	$10.52M	$9.02M	$6.62M	$7.52M
Low Forecast	$21.32M	$20.46M	$21.39M	$16.30M	$20.36M	$19.98M	$18.63M	$17.03M	$17.27M	$15.40M	$15.68M	$13.63M	$13.29M	$13.04M	$10.90M	$9.71M	$9.02M	$6.62M	$7.52M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.43%	0.99%	-2.34%	0.34%

MDxHealth SA's average Quarter SG&A projection for Jun 23 is $11.44M, based on 1 Wall Street analysts, with a range of $10.90M to $11.81M. The forecast indicates a -21.62% fall compared to MDXH last annual SG&A of $14.60M (Mar 23).

MDxHealth SA EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Dec 21	Mar 21
# Analysts	1	1	1	1	1	1	1	3	4	2	1	1	2	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.63	$-0.53	$-0.73	$-0.63
Avg Forecast	$-0.03	$-0.05	$-0.04	$-0.14	$-0.11	$-0.12	$-0.15	$-0.17	$-0.19	$-0.27	$-0.27	$-0.30	$-0.21	$-0.30	$-0.33	$-0.41	$-1.30	$-1.50	$-2.70
High Forecast	$-0.03	$-0.05	$-0.04	$-0.13	$-0.10	$-0.11	$-0.14	$-0.17	$-0.15	$-0.25	$-0.26	$-0.28	$-0.15	$-0.28	$-0.31	$-0.39	$-1.30	$-1.50	$-2.70
Low Forecast	$-0.03	$-0.05	$-0.05	$-0.14	$-0.11	$-0.12	$-0.15	$-0.17	$-0.25	$-0.28	$-0.29	$-0.31	$-0.26	$-0.31	$-0.34	$-0.43	$-1.30	$-1.50	$-2.70
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.52%	0.41%	0.49%	0.23%

According to undefined Wall Street analysts, MDxHealth SA's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MDXH previous annual EPS of $NaN (undefined).

MDxHealth SA Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
MDXH	MDxHealth SA	$2.37	$15.00	532.91%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy

MDXH Forecast FAQ

Is MDxHealth SA a good buy?

Yes, according to 12 Wall Street analysts, MDxHealth SA (MDXH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 83.33% of MDXH's total ratings.

What is MDXH's price target?

MDxHealth SA (MDXH) average price target is $15 with a range of $15 to $15, implying a 563.72% from its last price of $2.26. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will MDxHealth SA stock go up soon?

According to Wall Street analysts' prediction for MDXH stock, the company can go up by 563.72% (from the last price of $2.26 to the average price target of $15), up by 563.72% based on the highest stock price target, and up by 563.72% based on the lowest stock price target.

Can MDxHealth SA stock reach $3?

MDXH's average twelve months analyst stock price target of $15 supports the claim that MDxHealth SA can reach $3 in the near future.

What are MDxHealth SA's analysts' financial forecasts?

MDxHealth SA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $105.33M (high $108.3M, low $101.08M), average EBITDA is $-93.029M (high $-89.28M, low $-95.653M), average net income is $-25.738M (high $-24.628M, low $-26.492M), average SG&A $79.19M (high $81.43M, low $76M), and average EPS is $-0.544 (high $-0.521, low $-0.56). MDXH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $111M (high $114.58M, low $105.7M), average EBITDA is $-98.04M (high $-93.36M, low $-101M), average net income is $-12.224M (high $-11.466M, low $-12.737M), average SG&A $83.46M (high $86.15M, low $79.48M), and average EPS is $-0.259 (high $-0.242, low $-0.269).

Did the MDXH's actual financial results beat the analysts' financial forecasts?

Based on MDxHealth SA's last annual report (Dec 2021), the company's revenue was $22.24M, beating the average analysts forecast of $18.8M by 18.29%. Apple's EBITDA was $-23.897M, beating the average prediction of $-15.699M by 52.22%. The company's net income was $-31.163M, missing the average estimation of $-115M by -72.81%. Apple's SG&A was $7.65M, missing the average forecast of $14.14M by -45.85%. Lastly, the company's EPS was $-2.56, missing the average prediction of $-4.2 by -39.05%. In terms of the last quarterly report (Mar 2023), MDxHealth SA's revenue was $14.7M, beating the average analysts' forecast of $13.56M by 8.42%. The company's EBITDA was $-7.081M, missing the average prediction of $-11.975M by -40.87%. MDxHealth SA's net income was $-14.701M, missing the average estimation of $-19.537M by -24.75%. The company's SG&A was $14.6M, beating the average forecast of $10.19M by 43.23%. Lastly, the company's EPS was $-0.63, beating the average prediction of $-0.413 by 52.49%